[1]孙玉 郭守玉 龙明智.中心动脉压与靶器官损害的研究进展[J].心血管病学进展,2023,(5):457.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.017]
　SUN Yu,GUO Shou yu,LONG Ming zhi.Central Arterial Pressure and Target Organ Damage[J].Advances in Cardiovascular Diseases,2023,(5):457.[doi:10.16806/j.cnki.issn.1004-3934.2023.05.017]
点击复制

中心动脉压与靶器官损害的研究进展()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2023年5期
页码:
457
栏目:
综述
出版日期:
2023-05-25

文章信息/Info

Title:
Central Arterial Pressure and Target Organ Damage
作者:
孙玉1 郭守玉2 龙明智2
(1.南京医科大学第二附属医院,江苏 南京 210000;2.南京医科大学第二附属医院心内科,江苏 南京 210000)
Author(s):
SUN Yu 1; GUO Shou yu2; LONG Ming zhi2
The Second Affiliated Hospital of Nanjing Medical University,Nanjing 210000,Jiangsu, China; 2. Department of Cardiology,The Second Affiliated Hospital of Nanjing Medical University,Nanjing 210000,Jiangsu,China)
关键词:
中心动脉压; 靶器官损害; 外周动脉压
Keywords:
Central arterial pressure; Target organ damage; Peripheral arterial pressure
DOI:
10.16806/j.cnki.issn.1004-3934.2023.05.017
摘要:
高血压是21世纪对人类健康最具威胁性的慢性疾病之一，是全世界死亡归因的最主要危险因素，血压升高可显著增加冠状动脉粥样硬化性心脏病、心力衰竭、终末期肾病以及认知减退等并发症的发生率，被称为“无声杀手”。目前对于患者血压的监测仍以外周动脉压为主，治疗方案的选择同样以外周动脉压为依据。随着ASCOT-CAF?等试验结果的问世，大众开始重视中心动脉压的临床地位。因此，基于高血压在全球及中国的现状，综述原发性高血压患者中心动脉压对心、脑、肾等靶器官损害的影响，并简述不同抗高血压药对中心动脉压的治疗效果以及目前尚存的一些问题。
Abstract:
Hypertension is one of the most threatening chronic diseases to human health in the 21st century and is the main risk factor for attribution of death all over the world. High blood pressure can significantly increase coronary heart disease,heart failure,end-stage renal disease,cognitive decline and other complications,known as the “silent killer”. At present,peripheral arterial pressure is the main monitoring method for patients’ blood pressure,and the choice of treatment plan is also based on peripheral arterial pressure. However,with the advent o f ASCOT-CAF? and other trial results,the public began to pay attention to the clinical status of central arterial pressure. Therefore,based on the current situation of hypertension in the world and China,this paper describes in detail the effects of central arterial pressure in primary hypertension patients on the damage of heart,brain and kidney target organs,and briefly describes the therapeutic effects of different antihypertensive drugs on central arterial pressure and some existing problems

参考文献/References:


[1]Babbs CF. The origin of Korotkoff sounds and the accuracy of auscultatory blood pressure measurements[J]. J Am Soc Hypertens,2015,9(12):935-950.e933.

[2]NCD Risk Factor Collaboration(NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019:a pooled analysis of 1201 population-representative studies with 104 million participants[J]. Lancet,2021,398(10304):957-980.

[3]GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories,1990-2019:a systematic analysis for the Global Burden of Disease Study 2019[J]. Lancet,2020,396(10258):1223-1249.

[4]佚名.中国心血管健康与疾病报告2020[J]. 心肺血管病杂志,2021,40(9):885-889.

[5]McEniery CM,Cockcroft JR,Roman MJ,et al. Central blood pressure:current evidence and clinical importance[J]. Eur Heart J,2014,35(26):1719-1725.

[6]O’Rourke MF,Hashimoto J. Mechanical factors in arterial aging:a clinical perspective[J]. J Am Coll Cardiol,2007,50(1):1-13.

[7]Nakagomi A,Shoji T,Okada S,et al. Validity of the augmentation index and pulse pressure amplification as determined by the SphygmoCor XCEL device:a comparison with invasive measurements[J]. Hypertens Res,2018,41(1):27-32.

[8]Terentes-Printzios D,Gardikioti V,Vlachopoulos C. Central over peripheral blood pressure:an emerging issue in hypertension research[J]. Heart Lung Circ,2021,30(11):1667-1674.

[9]初少莉. 中心动脉压及其临床应用[J]. 中华高血压杂志,2007,15(4):269-271.

[10]Pauklin P,Eha J,Tootsi K,et al. Atrial fibrillation is associated with increased central blood pressure and arterial stiffness[J]. J Clin Hypertens(Greenwich),2021,23(8):1581-1587.

[11]Boutouyrie P,Chowienczyk P,Humphrey JD,et al. Arterial stiffness and cardiovascular risk in hypertension[J]. Circ Res,2021,128(7):864-886.

[12]Yusuf S,Pfeffer MA,Swedberg K,et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction:the CHARM-Preserved Trial[J]. Lancet,2003,362(9386):777-781.

[13]Vasan RS,Song RJ,Xanthakis V,et al. Aortic root diameter and arterial stiffness:conjoint relations to the incidence of cardiovascular disease in the Framingham Heart Study[J]. Hypertension,2021,78(5):1278-1286.

[14]Roman MJ,Devereux RB,Kizer JR,et al. High central pulse pressure is independently associated with adverse cardiovascular outcome the strong heart study[J]. J Am Coll Cardiol,2009,54(18):1730-1734.

[15]Ma Q,Li R,Wang L,et al. Temporal trend and attributable risk factors of stroke burden in China,1990-2019:an analysis for the Global Burden of Disease Study 2019[J]. Lancet Public Health,2021,6(12): e897-e906.

[16]Ceravolo R,Maio R,Pujia A,et al. Pulse pressure and endothelial dysfunction in never-treated hypertensive patients[J]. J Am Coll Cardiol,2003,41(10):1753-1758.

[17]蒋雄京,路方红,孙宁玲,等. 中心动脉压对心,脑,肾的影响是否一致?[J]. 中华高血压杂志,2006,14(8):600-602.

[18]Kim JY,Bushnell CD,Park JH,et al. Central aortic pressure and pulsatility index in acute ischemic stroke[J]. J Neuroimaging,2015,25(3):438-442.

[19]Fan F,Qi L,Jia J,et al. Noninvasive central systolic blood pressure is more strongly related to kidney function decline than peripheral systolic blood pressure in a Chinese community-based population[J]. Hypertension,2016,67(6):1166-1172.

[20]Fu S,Guo Y,Luo L,et al. Association of arterial stiffness and central hemodynamics with moderately reduced glomerular filtration rate in Chinese middle-aged and elderly community residents:a cross-sectional analysis[J]. BMC Nephrol,2018,19(1):103.

[21]沈卫,张正银,黄韵,等. 不同血压参数与原发性高血压伴微量白蛋白尿的相关性分析[J]. 现代生物医学进展,2016,16(36):7102-7105.

[22]Hashimoto J. Central hemodynamics and target organ damage in hypertension[J]. Tohoku J Exp Med,2014,233(1):1-8.

[23]Sun P,Yang Y,Cheng G,et al. Noninvasive central systolic blood pressure,not peripheral systolic blood pressure,independently predicts the progression of carotid intima-media thickness in a Chinese community-based population[J]. Hypertens Res,2019,42(3):392-399.

[24]Williams B,O’Rourke M. The Conduit Artery Functional Endpoint (CAFE) study in ASCOT[J]. J Hum Hypertens,2001,15(suppl 1):S69-S73.

[25]Wachtell K,Lehto M,Gerdts E,et al. Angiotensin Ⅱ receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol:the Losartan Intervention For End Point Reduction in Hypertension(LIFE) study[J]. J Am Coll Cardiol,2005,45(5):712-719.

[26]Morgan T,Lauri J,Bertram D,et al. Effect of different antihypertensive drug classes on central aortic pressure[J]. Am J Hypertens,2004,17(2):118-123.

[27]韩治伟,李建平. 不同药物对中心动脉压的影响[J]. 临床药物治疗杂志,2010,8(2):13-16.

[28]张毅. 中心动脉压及其变异性与亚临床靶器官损害的关系[J]. 中华高血压杂志,2017,25(2):127-129.

[29]Papaioannou TG,Argyris A,Protogerou AD,et al. Non-invasive 24 hour ambulatory monitoring of aortic wave reflection and arterial stiffness by a novel oscillometric device:the first feasibility and reproducibility study[J]. Int J Cardiol,2013,169(1):57-61.

相似文献/References:

[1]王瑞 惠红 张晓卉.长时血压变异性的相关研究进展[J].心血管病学进展,2021,(6):499.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.006]
　WANG RuiHUI HongZHANG Xiaohui. Long-Term Blood Pressure Variability[J].Advances in Cardiovascular Diseases,2021,(5):499.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.006]

更新日期/Last Update: 2023-06-29